HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shoji Fukushima Selected Research

4- (4- cyclohexyl- 2- methyloxazol- 5- yl)- 2- fluorobenzenesulfonamide

1/2005JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
7/2004Inhibition of azoxymethane-induced colon carcinogenesis in rats due to JTE-522, a selective cyclooxygenase-2 inhibitor.
12/2003Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shoji Fukushima Research Topics

Disease

72Neoplasms (Cancer)
07/2022 - 01/2002
47Carcinogenesis
10/2018 - 01/2002
20Carcinoma (Carcinomatosis)
10/2018 - 07/2002
16Body Weight (Weight, Body)
07/2022 - 05/2002
15Hyperplasia
10/2015 - 01/2002
9Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2022 - 08/2003
9Liver Cell Adenoma (Hepatocellular Adenoma)
04/2016 - 11/2004
8Hepatocellular Carcinoma (Hepatoma)
09/2019 - 11/2004
6Adenoma (Adenomas)
10/2018 - 01/2002
6Urinary Bladder Neoplasms (Bladder Cancer)
11/2010 - 01/2000
6Cystitis
11/2009 - 04/2003
5Chromosome Aberrations (Chromosome Abnormalities)
11/2016 - 08/2004
5Adenocarcinoma
03/2012 - 01/2002
5Fibrosis (Cirrhosis)
01/2010 - 01/2005
5Colonic Neoplasms (Colon Cancer)
03/2009 - 01/2002
5Aberrant Crypt Foci
01/2005 - 09/2002
4Infections
04/2022 - 05/2004
4Papilloma (Papillomatosis)
12/2013 - 08/2002
3Thrombocytopenia (Thrombopenia)
08/2022 - 01/2019
3Polyploidy
11/2016 - 04/2008
3Inflammation (Inflammations)
10/2014 - 11/2009
2Breast Neoplasms (Breast Cancer)
08/2022 - 01/2021
2Neutropenia
08/2022 - 01/2021
2Neoplasm Metastasis (Metastasis)
03/2021 - 01/2018
2Atrophy
11/2010 - 04/2006
2Cholestasis
12/2009 - 09/2009
2Kidney Neoplasms (Kidney Cancer)
12/2009 - 12/2004
2Transitional Cell Carcinoma
01/2009 - 12/2003
2Schistosomiasis (Bilharziasis)
08/2008 - 01/2000

Drug/Important Bio-Agent (IBA)

23CarcinogensIBA
03/2013 - 01/2000
15Glutathione Transferase (Glutathione S-Transferase)IBA
10/2018 - 08/2003
11Proteins (Proteins, Gene)FDA Link
08/2022 - 08/2003
11Diethylnitrosamine (N-Nitrosodiethylamine)IBA
03/2013 - 05/2002
88-Hydroxy-2'-DeoxyguanosineIBA
08/2008 - 02/2002
7Pharmaceutical PreparationsIBA
03/2020 - 12/2004
7Messenger RNA (mRNA)IBA
02/2015 - 08/2003
7ArsenicIBA
01/2007 - 01/2002
6Phenobarbital (Luminal)FDA Link
01/2017 - 02/2002
6ethyl tert-butyl ether (ETBE)IBA
10/2015 - 11/2011
6Cacodylic Acid (Cacodylate)IBA
06/2006 - 01/2002
5Cisplatin (Platino)FDA LinkGeneric
09/2019 - 11/2002
5PlatinumIBA
09/2019 - 05/2003
5Drinking WaterIBA
10/2018 - 08/2004
5DNA (Deoxyribonucleic Acid)IBA
11/2015 - 08/2004
5Proliferating Cell Nuclear Antigen (PCNA)IBA
08/2008 - 03/2002
41,4-dioxane (dioxane)IBA
10/2018 - 08/2008
4ErbB Receptors (EGF Receptor)IBA
01/2018 - 08/2003
4ButylhydroxybutylnitrosamineIBA
12/2013 - 12/2003
4Ethanol (Ethyl Alcohol)IBA
03/2013 - 05/2002
4Thioacetamide (Thioacetamid)IBA
05/2008 - 01/2005
3NivolumabIBA
07/2022 - 12/2018
3Irinotecan (Camptosar)FDA LinkGeneric
06/2019 - 11/2002
3Carbon Nanotubes (Carbon Nanotube)IBA
11/2016 - 10/2013
3AsbestosIBA
11/2016 - 10/2013
3NitrosaminesIBA
02/2015 - 05/2002
3Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
03/2013 - 02/2002
3nitrosobenzylmethylamineIBA
03/2013 - 05/2002
3EnzymesIBA
12/2009 - 05/2002
3Carbon Tetrachloride (Tetrachloromethane)IBA
02/2008 - 05/2002
3AzoxymethaneIBA
01/2007 - 07/2004
32- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA
01/2007 - 07/2002
3Transforming Growth Factor alpha (TGF-alpha)IBA
06/2006 - 01/2004
3beta CateninIBA
01/2006 - 09/2005
31,2-Dimethylhydrazine (1,2 Dimethylhydrazine)IBA
01/2005 - 12/2003
3Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
01/2005 - 12/2003
34- (4- cyclohexyl- 2- methyloxazol- 5- yl)- 2- fluorobenzenesulfonamideIBA
01/2005 - 12/2003
3Dimenhydrinate (DMH)FDA LinkGeneric
01/2005 - 12/2003
3monomethylarsonic acid (MSMA)IBA
08/2004 - 07/2002
2abemaciclibIBA
08/2022 - 01/2021
2Indicators and Reagents (Reagents)IBA
01/2021 - 07/2009
2osimertinibIBA
01/2020 - 01/2018
2quinolineIBA
01/2018 - 09/2002
2SolutionsIBA
11/2017 - 08/2004
2Corn Oil (Oil, Corn)IBA
01/2017 - 09/2002
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2015 - 01/2007
2Biomarkers (Surrogate Marker)IBA
02/2015 - 03/2009
2CytokinesIBA
10/2014 - 05/2002
2MineralsIBA
05/2013 - 01/2012
2Environmental CarcinogensIBA
03/2013 - 07/2002
2Cytochrome P-450 CYP2E1 (CYP2E1)IBA
03/2013 - 12/2007
2Ether (Diethyl Ether)IBA
01/2013 - 12/2004
2Cadherins (E-Cadherin)IBA
03/2012 - 01/2006
2Epidermal Growth Factor (EGF)IBA
03/2012 - 11/2006
2Peptides (Polypeptides)IBA
03/2012 - 08/2003
2TriterpenesIBA
03/2010 - 06/2008
2L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2010 - 01/2010
2ClofibrateFDA Link
12/2009 - 11/2004
2potassium bromateIBA
12/2009 - 03/2008
2pirinixic acidIBA
12/2009 - 11/2004
2Peroxisome ProliferatorsIBA
12/2009 - 11/2004
2p38 Mitogen-Activated Protein KinasesIBA
11/2009 - 04/2003
2Growth Factor ReceptorsIBA
11/2009 - 11/2006
2NF-kappa B (NF-kB)IBA
11/2009 - 04/2003
2Bromodeoxyuridine (BrdU)IBA
05/2009 - 10/2005
2QuinoxalinesIBA
03/2009 - 05/2002
2Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
08/2008 - 01/2006

Therapy/Procedure

5Oral Administration
01/2014 - 01/2002
4Chemoprevention
01/2007 - 01/2000
2Therapeutics
07/2022 - 03/2004
2Ligation
12/2009 - 09/2009